Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Interleukin-2 correction of defectivein vitro T-cell mitogenesis in patients with common varied immunodeficiency


We studied the ability of phytohemagglutinin (PHA) and two anti-T-cell monoclonal antibodies, OKT3 and Pan T2, to induce interleukin-2 (IL2) production and proliferation in peripheral blood lymphocytes (PBL) from 14 patients with combined varied immunodeficiency (CVI). The median values of endogenous IL2 produced by mitogen-stimulated PBL was significantly lower in patients than controls irrespective of the mitogen used. The patients, taken as a group, had a significantly decreasedin vitro PBL response to mitogen stimulation when compared to controls. With the addition of a highly purified human IL2 preparation, the proliferative response in the majority of patients was significantly improved with all mitogens. Three patient groups could be distinguished: Group A (3/14) had full restoration of proliferative response with the addition of IL2, Group B (5/14) had partial restoration, and Group C (6/14) had no significant response. The monoclonal antibody, Pan T2, recognized a T-cell proliferative defect in 5 of 14 patients which neither PHA nor OKT3 recognized. This was not significantly corrected by the addition of IL2. This T-cell proliferative defect correlated with the lack of B-cell proliferation and immunoglobulin production in response to B-cell mitogens in three-fourths of the patients assayed. These data show that CVI patients are a heterogeneous group but have in common a decreasedin vitro production of IL2 resulting in a proliferative defect which is correctable at least in part,in vitro, in the majority by the addition of purified IL2.

This is a preview of subscription content, log in to check access.


  1. 1.

    Gupta S, Good RA: Markers of human lymphocyte subpopulations in primary immunodeficiency and lymphoproliferative disorders. Semin Hematol 17:1–29, 1980

  2. 2.

    Webster ADB, Anderson GL: Identification and function of T cells in the peripheral blood of patients with hypogammaglobulinemia. Clin Exp Immunol 8:499–504, 1974

  3. 3.

    WHO. Immunodeficiency Report of a WHO scientific group. Clin Immunol Immunopathol 13:296–359, 1979

  4. 4.

    Cunningham-Rundles S, Cunningham-Rundles C, Ma DI, Siegal SP, Kosloff C, Good RA: Impaired proliferative response to B lymphocyte activators in common variable immunodeficiency. J Clin Immunol 1:65–72, 1981

  5. 5.

    Siegal GP, Good RA: Human lymphocyte differentiation markers and their application to immune deficiency and lymphoproliferative disease. Clin Haematol 6:355–422, 1977

  6. 6.

    Preud'Homme JL, Giscelli C, Seligmann M: Immunoglobulins on the surface of lymphocytes in 50 patients with primary immunodeficiency disease. Clin Immunol Immunopathol 1:241–256, 1973

  7. 7.

    Waldmann TA, Blaese RM, Broder S, Krakauer RS: NIH Conference: Disorders of suppressor immunoregulatory cells in the pathogenesis of immunodeficiency and autoimmunity. Ann Intern Med 88:226–238, 1978

  8. 8.

    Schwartz SA, Choi YS, Shou L: Modulatory effects on immunoglobulin synthesis and secretion by lymphocytes from immunodeficient patients. J Clin Invest 50:1176–1187, 1976

  9. 9.

    Siegal FP, Siegal M, Good RA: Suppression of plasma cell formation by leukocytes from hypogammaglobulinemia patients. J Clin Invest 58:109–122, 1976

  10. 10.

    Siegal FP, Siegal M, Good RA: Role of helper, suppressor and B cell defects in the pathogenesis of the hypogammaglobulinemias. N Engl J Med 299:172–178, 1978

  11. 11.

    De la Concha EG, Oldham G, Webster ABD, Asherson GL, Platts-Mills TAE: Quantitative measurements of T and B cell function in “variable” primary hypogammaglobulinemia: Evidence for a consistent B cell defect. Clin Exp Immunol 27:208–215, 1977

  12. 12.

    Smith KA: T cell growth factor. Immunol Rev 51:337–357, 1980

  13. 13.

    Palacios K, Moller G: HLA-DR antigens render resting T cells sensitive to Interleukin 2 and induce production of the growth factor in the autologous mixed lymphocyte reaction. Cell Immunol 63:143–152, 1981

  14. 14.

    Ruscetti FW, Gallo RC: Human T lymphocyte growth factor: Regulation of growth and function of T lymphocytes. Blood 57:379–394, 1981

  15. 15.

    Immunodeficiency: World Health Organization Technical Report Series. Geneva, WHO, 1978

  16. 16.

    Koziner B, Filippa DA, Mertelsmann RA, Gupta S, Clarkson BD, Good RA, Siegal FP: Characterization of malignant lymphomas in leukemic phase by multiple differentiation markers of leukemic cells: Correlations with clinical features and conventional morphology. Am J Med 63:556–567, 1977

  17. 17.

    Koziner B, Kempin S, Passe S, Gee TS, Good RA, Clarkson BD: Characterization of B neoplasias in leukemic phase. A tentative immuno-morphological classification. Blood 56:815–823, 1980

  18. 18.

    Ledbetter JA, Evans RL, Lipinski M, Cunningham-Rundles C, Good RA, Herzenberg LA: Evolutionary conservation of surface molecules that distinguish T lymphocyte helper/inducer and T cytotoxic/suppressor subpopulations in mouse and man. J Exp Med 153:310–323, 1981

  19. 19.

    Wang CY, Bushkin Y, Peng R, Feldman S, Welte K, Venuta S, Mertelsmann R: A T-cell specific monoclonal antibody recognizing a p25–28 molecular complex involved in the triggering of IL2 production (submitted for publication)

  20. 20.

    Welte K, Venuta S, Wang CY, Feldman S, Ciobanu N, Kruger G, Feickert J, Flomenberg N, Moore MAS, Mertelsmann R: Human Interleukin 2: Physiology, Biochemistry and pathophysiology in lymphoblastic leukemias and immunodeficiency syndromes.In Modern Trends in Human Leukemia V, R Neth (ed). New York, Springer Verlag (in press)

  21. 21.

    Welte K, Wang CY, Mertelsmann R, Venuta S, Feldman SP, Moore MAS: Purification of human Interleukin 2 to apparent homogeneity and its molecular heterogeneity. J Exp Med 156:454–464, 1982

  22. 22.

    Venuta S, Mertelsmann R, Welte K, Feldman SF, Wang CY, Moore MAS: Production and regulation of Interleukin 2 in human lymphoblastic leukemias studied with T cell monoclonal antibodies. Blood 61:781–789, 1983

  23. 23.

    Gillis S, Smith A: Long term culture of tumor specific cytotoxic T cells. Nature Lond 268:154–156, 1977

  24. 24.

    Gillis S, Fernm M, Ou W, Smith KA: T cell growth factor: Parameters of production and quantitative microassay for activity. J Immunol 120:2027–2031, 1978

  25. 25.

    Saiki O, Ralph P: Three distinct stages of B-cell defects in common varied immunodeficiency. Proc Natl Acad Sci USA 79:6008–6012, 1982

  26. 26.

    Saiki O, Ralph P: Induction of human immunoglobulin secretion. 1. Synergistic effect of B cell mitogen Cowan I plus T cell mitogens or factors. J Immunol 127:1044–1047, 1981

  27. 27.

    Kruskal WH, Wallis WA: Use of ranks in one-criteria analysis. J Am Stat Assoc 47:583, 1952

  28. 28.

    Kruskal WH, Wallis WA: Use of ranks in one-criteria analysis. J Am Stat Assoc 48:907, 1953

  29. 29.

    Bahn AK: Basic Medical Statistics. New York, Grune & Stratton, 1972, pp 144–153

  30. 30.

    Lopez-Botet M, Fontan G, Rodriguez MCG, Landazuri MO: Relationship between IL2 synthesis and the proliferative response to PHA in different primary immunodeficiencies. J Immunol 128:679–683, 1982

  31. 31.

    Sykora KW, Kolitz J, Szabo P, Grzeschik KH, Moore MAS, Mertelsmann R: The human Interleukin 2 gene is located on chromosome 4. Proc Am Assoc Cancer Res (in press), 1984

Download references

Author information

Correspondence to G. Kruger.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kruger, G., Welte, K., Ciobanu, N. et al. Interleukin-2 correction of defectivein vitro T-cell mitogenesis in patients with common varied immunodeficiency. J Clin Immunol 4, 295–303 (1984).

Download citation

Key words

  • Combined varied immunodeficiency
  • interleukin-2
  • T-cell lymphocytes
  • B-cell lymphocytes
  • mitogen response